Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …
At historically low interest rates, refinancing can seem tempting; but applications for refinance could be denied for various reasons. Underwriters need assurances that…
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights.
Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Illumina Company is mentioned.
We assess its relevance and importance to carry out an overall sentiment valuation of Illumina, Inc. (ILMN).
You can view the trend designation for each individual article below.
We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Illumina stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
In a setback for EU antitrust regulators, an adviser to Europe's top court has criticized the decision to block Illumina Inc's ILMN $7.1 billion bid for Grail Inc., stating that they exceeded their powers.
Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.
Activist investor Carl Icahn has opted against pursuing a fresh challenge to Illumina Inc's ILMN board, a move that spares the U.S. gene sequencing company from facing its second proxy battle in consecutive years.
Deep-pocketed investors have adopted a bearish approach towards Illumina ILMN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend:Neutral
March 7, 2024 (12:30) / "PR Newswire" (by Moligo Technologies)
Wilmington, Delaware, United States, March 04, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global spatial genomics & transcriptomics market is estimated to flourish at a CAGR of 17% from 2023 to 2033.
Although U.S. stocks closed lower on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
In Article Trend:Somewhat-Bullish
February 27, 2024 (08:09) / "PR Newswire" (by Illumina)
SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- On February 26, 2024, Illumina Inc. ( NASDAQ: ILMN ) a global leader in DNA sequencing and array-based technologies, announced that Jenny Zheng joins Illumina as Senior Vice President and General Manager of Greater China, and a member of the global ...
In Article Trend:Bullish
February 27, 2024 (02:00) / "Benzinga" (by Globe Newswire)
NEW YORK, Feb. 26, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Illumina, Inc.
In Article Trend:Neutral
February 26, 2024 (23:29) / "Motley Fool" (by Eric Volkman)
SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- Armonica Technologies, Inc., a pioneer in sample-prep free direct optical DNA sequencing, today announced the appointment of biotech veteran Emily Milsovic to the Board of Directors.
Wilmington, Delaware, United States, Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global microarray scanners market is estimated to flourish at a CAGR of 7.5% from 2023 to 2031.
In Article Trend:Somewhat-Bullish
February 18, 2024 (06:50) / "Stocknews.com" (by Defense World Staff)
Illumina ( NASDAQ:ILMN - Get Free Report ) was upgraded by equities researchers at StockNews.com from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Friday. ILMN has been the subject of a number of other reports. Sanford C.
In Article Trend:Somewhat-Bullish
February 16, 2024 (06:34) / "Stocknews.com" (by Defense World Staff)
Illumina ( NASDAQ:ILMN - Get Free Report ) was upgraded by stock analysts at StockNews.com from a "hold" rating to a "buy" rating in a report issued on Friday. A number of other equities analysts have also weighed in on the stock.
In Article Trend:Somewhat-Bullish
February 15, 2024 (12:30) / "Benzinga" (by Globe Newswire)
Chicago, Feb. 15, 2024 ( GLOBE NEWSWIRE ) -- Carrier Screening market in terms of revenue was estimated to be worth $2.2 billion in 2023 and is poised to reach $5.4 billion by 2028, growing at a CAGR of 19.7% from 2023 to 2028 according to a latest report published by MarketsandMarkets™.
In Article Trend:Somewhat-Bullish
February 12, 2024 (13:00) / "Investors Business Daily" (by Investor's Business Daily)
New York, United States, Feb. 12, 2024 ( GLOBE NEWSWIRE ) -- This study examines the effects of uncommon diseases on a significant portion of the global population. There are over 7000 uncommon diseases, and inadequate information is available for many of them, limiting diagnostic and therapeutic ...
In Article Trend:Neutral
February 9, 2024 (18:18) / "Benzinga" (by Avi Kapoor)
Shares of Take-Two Interactive Software, Inc. TTWO fell sharply during Friday's session following third-quarter results. Take-Two reported third-quarter total net bookings of $1.34 billion, down 3% year-over-year.
In Article Trend:Neutral
February 9, 2024 (14:32) / "Benzinga" (by Vandana Singh)
Thursday, Illumina Inc ILMN reported fourth-quarter 2023 sales of $1.12 billion, up 4% Y/Y, beating the consensus of $1.09 billion. The company reported adjusted EPS of $0.14, surpassing the consensus estimate of $0.02.
Chicago, Feb. 09, 2024 ( GLOBE NEWSWIRE ) -- Molecular Cytogenetics market in terms of revenue was estimated to be worth $3.1 billion in 2023 and is poised to reach $4.9 billion by 2028, growing at a CAGR of 9.9% from 2023 to 2028 according to a latest report published by MarketsandMarkets™.
In Article Trend:Neutral
February 9, 2024 (09:57) / "Benzinga" (by Avi Kapoor)
U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 15 points on Friday. Shares of Expedia Group, Inc. EXPE fell sharply in today's pre-market trading after the company reported fourth-quarter financial results and named Ariane Gorin as CEO.
In Article Trend:Neutral
February 8, 2024 (21:05) / "PR Newswire" (by Inc.)
SAN DIEGO, Feb. 8, 2024 /PRNewswire/ -- Illumina, Inc. ( Nasdaq: ILMN ) ( "Illumina" or the "company" ) today announced its financial results for the fourth quarter and fiscal year 2023, which include the consolidated financial results for GRAIL.
In Article Trend:Neutral
February 8, 2024 (19:05) / "Benzinga" (by Piero Cingari)
Major U.S. stock averages traded on a mixed note at midday in New York, with the S&P 500 grappling with the psychological resistance level of 5,000, while the tech-heavy Nasdaq 100 managed to reach fresh record highs. On a relatively data-thin day, Federal Reserve officials continued to dominate ...
Get a deeper insight into the potential performance of Illumina (ILMN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
In Article Trend:Neutral
February 2, 2024 (23:00) / "Investors Business Daily" (by ALAN R. ELLIOTT)
Wilmington, Delaware, United States, Feb. 02, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global micro-RNA market is estimated to flourish at a CAGR of 29.4% from 2023 to 2033.
In Article Trend:Somewhat-Bullish
February 1, 2024 (14:00) / "PR Newswire" (by Volta Labs Inc.)
BOSTON, Feb. 1, 2024 /PRNewswire/ -- , a genomics applications company, announced today the introduction of the Callisto™ Sample Prep System, a benchtop instrument with many pre-optimized applications that reduces operational requirements and costs in the laboratory and clinic that were ...
In Article Trend:Somewhat-Bullish
January 30, 2024 (06:20) / "Stocknews.com" (by Defense World Staff)
Illumina ( NASDAQ:ILMN - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Tuesday. Several other analysts have also recently commented on the company.
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and,
moreover, are not trading signals.
When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market
as a result of using the information contained on the site.
This website uses cookies to ensure you get the best experience on our website